Novel complex identified as target for autoimmune diseases
Researchers have found that the interaction between BRISC and SHMT2 may be responsible for the overproduction of cytokines during an autoimmune response, leading to the development of new therapies for diseases, such as lupus, through targeting this complex.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>